| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/14/1999 | CA2012732C Production of modified pe40 |
| 09/14/1999 | CA1340741C Cloned genes encoding ig-cd4 fusion protiens and the use thereof |
| 09/11/1999 | CA2231968A1 Method of producing a nicotine medicament |
| 09/10/1999 | WO1999045127A2 Enhanced prodrug activation |
| 09/10/1999 | WO1999045126A2 Enhanced prodrug activation |
| 09/10/1999 | WO1999045054A1 Biodegradable polymers based on natural and renewable raw materials, especially isosorbite |
| 09/10/1999 | WO1999045032A1 Novel derivatives of cyclodextrins |
| 09/10/1999 | WO1999045026A1 Method for increasing the serum half-life of a biologically active molecule |
| 09/10/1999 | WO1999045020A1 Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs |
| 09/10/1999 | WO1999044643A1 Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles |
| 09/10/1999 | WO1999044642A1 Pharmaceutical compositions and their use |
| 09/10/1999 | WO1999044641A1 Transmucous sorbefacients |
| 09/10/1999 | WO1999044629A2 Utilization of cd137 in order to promote the proliferation of peripheral monocytes |
| 09/10/1999 | WO1999044622A1 Inorganic nitrite and organic acid in combination as topical antiviral composition |
| 09/10/1999 | WO1999044617A1 Activated vitamin d3 emulsion-type lotions |
| 09/10/1999 | WO1999044614A1 Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption |
| 09/10/1999 | WO1999044604A1 Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate |
| 09/10/1999 | WO1999044591A1 Extended release dosage form |
| 09/10/1999 | WO1999044589A1 Oral pellet with immediate release comprising glycerides subjected to polyglycolysis, method for making same |
| 09/10/1999 | WO1999044586A1 Topical formulation of oil-in-water type as a carrier for providing a reduced irritant effect |
| 09/10/1999 | WO1999044585A1 Topical formulation of the oil-in-water type, comprising galactolipid material as emulsifier, with a prolonged effect of an incorporated active substance |
| 09/10/1999 | WO1999044584A1 Emulsion preconcentrates containing cyclosporin or a macrolide |
| 09/10/1999 | WO1999044581A2 Pharmaceutical composition of topiramate |
| 09/10/1999 | WO1999044580A1 Fast disintegrating tablets |
| 09/10/1999 | WO1999044578A1 Formulations with an anti-viral effect |
| 09/10/1999 | WO1999044573A1 Composition and means for treating dry mouth |
| 09/10/1999 | WO1999044557A1 Hydrogels containing cross-linked carboxylic acid-hydroxy alcoholpolymers for use in drug delivery |
| 09/10/1999 | WO1999033486A9 Composition and method for dermal and transdermal administration of a cytokine |
| 09/10/1999 | WO1999033451A3 Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin |
| 09/10/1999 | WO1999031262A3 Needle-free injection of formulated nucleic acid molecules |
| 09/10/1999 | WO1999027102A9 Cd4+ t-lymphocyte protease genes and inhibitors thereof |
| 09/10/1999 | WO1999024472A8 Glycosylated antibodies and antibody fragments having reactive ketone groups |
| 09/10/1999 | WO1999013907A9 Methods to improve immunogenicity of antigens and specificity of antibodies |
| 09/10/1999 | CA2324279A1 Biodegradable polymers based on natural and renewable raw materials, especially isosorbite |
| 09/10/1999 | CA2323731A1 Topical formulation of oil-in-water type as a carrier for providing a reduced irritant effect |
| 09/10/1999 | CA2322850A1 Topical formulation of the oil-in-water type, comprising galactolipid material as emulsifier, with a prolonged effect of an incorporated active substance |
| 09/10/1999 | CA2322796A1 Pharmaceutical compositions containing the phospholipase inhibitor sodium ¬¬3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl|oxy|acetate |
| 09/10/1999 | CA2322684A1 Utilization of cd137 in order to promote the proliferation of peripheral monocytes |
| 09/10/1999 | CA2322664A1 Enhanced prodrug activation |
| 09/10/1999 | CA2322450A1 Formulations having an antiviral action |
| 09/10/1999 | CA2322199A1 Inorganic nitrite and organic acid in combination as topical antiviral composition |
| 09/09/1999 | DE19809913A1 Biodegradable Polymere auf der Basis von natürlichen und nachwachsenden Rohstoffen insbesondere Isosorbit Biodegradable polymers based on natural and renewable raw materials in particular isosorbitol |
| 09/09/1999 | DE19809719A1 Aqueous dispersion for binder and coating for medicine |
| 09/09/1999 | DE19809304A1 Formulierungen mit antiviraler Wirkung Formulations having antiviral activity |
| 09/09/1999 | DE19808865A1 Production of crosslinked structures of colloidal dimensions, e.g. hollow spheres or films, useful as lubricants, drug delivery systems, contrast agents, therapy vectors, chromatograhic media, magnetic data storage coatings, etc. |
| 09/09/1999 | DE19802569A1 New fragment of the lethal toxin from Clostridium bacterium, useful for treating cancer |
| 09/08/1999 | EP0940144A1 Bioactive polymer product |
| 09/08/1999 | EP0940138A1 Lubrication assistant and process for the preparation of ethyl stearate used therein |
| 09/08/1999 | EP0940137A1 Lip care composition containing acexamic acid and uses |
| 09/08/1999 | EP0939819A1 Mini-e1a genes and gene products |
| 09/08/1999 | EP0939818A1 Recombinant toxin fragments |
| 09/08/1999 | EP0939771A1 Water soluble lipidated arabinogalactan |
| 09/08/1999 | EP0939655A1 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity |
| 09/08/1999 | EP0939641A1 Topical products as prophylactic or curative agents for bacterial skin infections |
| 09/08/1999 | EP0939640A1 Improvements in polymer compositions for chemotherapy and methods of treatment using the same |
| 09/08/1999 | EP0939638A1 Injectable formulations of avermectins and milbemycins |
| 09/08/1999 | EP0939631A1 Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms |
| 09/08/1999 | EP0939624A1 Effervescent bisphosphonate formulation |
| 09/08/1999 | EP0939623A1 Oral delayed immediate release formulation and method of preparation therefor |
| 09/08/1999 | EP0830128A4 Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell |
| 09/08/1999 | EP0793517B1 Device for enhancing electrotransport agent delivery |
| 09/08/1999 | EP0670713B1 A pharmaceutical formulation |
| 09/08/1999 | EP0621880B1 Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
| 09/08/1999 | CN1228028A Use of histamine for therapeutic purposes |
| 09/08/1999 | CN1228022A Parenteral paclitaxel stable non-toxic formulation |
| 09/08/1999 | CN1228021A Compositions comprising microparticles of water-insoluble substances and method for preparing same |
| 09/08/1999 | CN1228020A Multi-layered osmotic device |
| 09/08/1999 | CN1228019A Granulates comprising water soluble compound and cellulose |
| 09/08/1999 | CN1227743A Trovafloxacin mesylate tablet |
| 09/07/1999 | US5948878 Copolymerization of a diprimary amine and other comonomer |
| 09/07/1999 | US5948818 Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
| 09/07/1999 | US5948767 Transport of active material into cells; drug delivery |
| 09/07/1999 | US5948751 X14-mannitol |
| 09/07/1999 | US5948750 Conjugates useful in the treatment of prostate cancer |
| 09/07/1999 | US5948749 Mixture of a divinylbenzene-styrene copolymer powder absorbent and biological active peptide |
| 09/07/1999 | US5948688 Passing laser beam through suspension of lipophilic oligosaccharide antibiotic and carrier liquid, measuring scattering of light, determining hydrodynamic radius of particles or portion of particles with specific radius |
| 09/07/1999 | US5948675 Host-vector system which can be used in gene therapy |
| 09/07/1999 | US5948430 Water soluble film for oral administration with instant wettability |
| 09/07/1999 | US5948420 Gelled mixture of cationic polymer, hydrophobic ester, propylene or butylene glycol and glycerine |
| 09/07/1999 | US5948416 Stable topical compositions |
| 09/07/1999 | US5948401 Cationic therapeutic systems |
| 09/07/1999 | US5948397 Skin care treatment for embalmed bodies |
| 09/07/1999 | US5948392 Stable sulfide compositions, uses, and process for preparation thereof |
| 09/07/1999 | US5948389 Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics |
| 09/07/1999 | US5948386 Conjugate and method for forming aminomethyl phosphorus conjugates |
| 09/07/1999 | US5948385 Antimicrobial materials |
| 09/07/1999 | US5948384 Particulate agents |
| 09/07/1999 | CA2128795C A virus-safe blood coagulation factor xiii preparation |
| 09/07/1999 | CA2007752C Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof |
| 09/02/1999 | WO1999043817A1 High affinity humanized anti-cea monoclonal antibodies |
| 09/02/1999 | WO1999043816A1 High affinity humanized anti-tag-72 monoclonal antibodies |
| 09/02/1999 | WO1999043813A1 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 09/02/1999 | WO1999043752A1 Compositions for transporting negatively charged substances |
| 09/02/1999 | WO1999043361A1 Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates |
| 09/02/1999 | WO1999043359A1 Nanoparticles comprising polyisobutylcyanoacrylate and cyclodextrins |
| 09/02/1999 | WO1999043358A1 Dendrimeric fullerene derivatives, method for producing same and their use as neuroprotectors |
| 09/02/1999 | WO1999043357A1 Indolicidin and cationic peptides conjugated with polymers |
| 09/02/1999 | WO1999043355A2 Formulations containing oxaliplatin |
| 09/02/1999 | WO1999043350A1 Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin |
| 09/02/1999 | WO1999043349A1 Mucosal microparticle conjugate vaccine |